Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenagamtide vs Semaglutide in Obesity (AMAZE 7)
NCT07668414Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of amycretin in obesity, sponsored by Novo Nordisk. Started Sep 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07668414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668414.